NCT00184509

Brief Summary

The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at below P25 for phase_3 schizophrenia

Timeline
Completed

Started Feb 1993

Longer than P75 for phase_3 schizophrenia

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 1993

Completed
5.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 1998

Completed
7.4 years until next milestone

First Submitted

Initial submission to the registry

September 15, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 16, 2005

Completed
Last Updated

January 26, 2017

Status Verified

January 1, 2017

First QC Date

September 15, 2005

Last Update Submit

January 25, 2017

Conditions

Schizophrenia

Keywords

schizophreniapsychosocial treatmentoutcome

Outcome Measures

Primary Outcomes (1)

  • Rehospitalizations and psychotic relapse at two years

Secondary Outcomes (1)

  • Psychopathology, psychosocial changes, functioning, antipsychotic medication

Interventions

integrated psychosocial treatment (behavior)BEHAVIORAL

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • first-episode schizophrenia

You may not qualify if:

  • acute psychosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Norwegian University of Science and Technology

Trondheim, N-7000, Norway

Location

Related Publications (4)

  • Sigrunarson V, Grawe RW, Lydersen S, Morken G. Predictors of long term use of psychiatric services of patients with recent-onset schizophrenia: 12 years follow-up. BMC Psychiatry. 2017 Jan 14;17(1):18. doi: 10.1186/s12888-016-1186-x.

    PMID: 28088223DERIVED

  • Sigrunarson V, Grawe RW, Morken G. Integrated treatment vs. treatment-as-usual for recent onset schizophrenia; 12 year follow-up on a randomized controlled trial. BMC Psychiatry. 2013 Jul 30;13:200. doi: 10.1186/1471-244X-13-200.

    PMID: 23898805DERIVED

  • Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008 Apr 30;8:32. doi: 10.1186/1471-244X-8-32.

    PMID: 18447935DERIVED

  • Morken G, Grawe RW, Widen JH. Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia. J Clin Psychiatry. 2007 Apr;68(4):566-71. doi: 10.4088/jcp.v68n0409.

    PMID: 17474812DERIVED

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • K. Gunnar Gøtestam, MD

    Norwegian University of Science and Technology

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 15, 2005

First Posted

September 16, 2005

Study Start

February 1, 1993

Study Completion

May 1, 1998

Last Updated

January 26, 2017

Record last verified: 2017-01

Locations

NO(1)